2024
Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Senna M, Mostaghimi A, Ohyama M, Sinclair R, Dutronc Y, Wu W, Yu G, Chiasserini C, Somani N, Holzwarth K, King B. Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2. Journal Of The European Academy Of Dermatology And Venereology 2024, 38: 583-593. PMID: 38391212, DOI: 10.1111/jdv.19665.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlopeciaAlopecia AreataAzetidinesHumansJanus Kinase InhibitorsPurinesPyrazolesSulfonamidesConceptsSafety of baricitinibSALT scoreSevere alopecia areataPhase 3 trialAlopecia areataSevere AATract infectionsFrequent treatment-emergent adverse eventsMixed respondersWeeks of continuous therapyTreatment-emergent adverse eventsCreatine phosphokinase increaseUpper respiratory tract infectionUrinary tract infectionMaintenance of efficacyProportion of patientsRespiratory tract infectionsTreated with 2 mgLong-term efficacyLong-term treatmentJanus kinase inhibitorsJanus kinaseEyelash regrowthWeek-52Treatment discontinuation
2020
The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Peterson D, Damsky W, King B. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Journal Of The American Academy Of Dermatology 2020, 82: e223-e226. PMID: 32278797, PMCID: PMC7144601, DOI: 10.1016/j.jaad.2020.03.099.Peer-Reviewed Original ResearchMeSH KeywordsArthritis, RheumatoidAzetidinesBetacoronavirusColitis, UlcerativeCoronavirus InfectionsCOVID-19CytokinesDermatitis, AtopicHeterocyclic Compounds, 3-RingHumansImmunomodulationJanus KinasesNitrilesPandemicsPiperidinesPneumonia, ViralPrimary MyelofibrosisPurinesPyrazolesPyrimidinesPyrrolesRandomized Controlled Trials as TopicSARS-CoV-2STAT Transcription FactorsSulfonamidesBaricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
Simpson E, Lacour J, Spelman L, Galimberti R, Eichenfield L, Bissonnette R, King B, Thyssen J, Silverberg J, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman‐Yassky E, Beck L, Janes J, DeLozier A, Gamalo M, Brinker D, Cardillo T, Nunes F, Paller A, Wollenberg A, Reich K. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. British Journal Of Dermatology 2020, 183: 242-255. PMID: 31995838, DOI: 10.1111/bjd.18898.Peer-Reviewed Original ResearchConceptsSevere ADBREEZE-AD1BREEZE-AD2Topical corticosteroidsInadequate responseWeek 1Global assessmentConcomitant topical corticosteroidsSafety of baricitinibSignificant haematological changesCommon adverse eventsPhase II studyPrimary end pointSevere atopic dermatitisAtopic dermatitis severityInvestigator's Global AssessmentPhase III trialsSelective Janus kinase 1Weeks of treatmentNight-time awakeningsNew safety concernsDaily placeboMonotherapy trialsCardiovascular eventsGastrointestinal perforation
2018
Ruxolitinib for the treatment of severe alopecia areata
Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. Journal Of The American Academy Of Dermatology 2018, 80: 566-568. PMID: 30195572, DOI: 10.1016/j.jaad.2018.08.040.Peer-Reviewed Original Research
2017
JAK inhibitors in dermatology: The promise of a new drug class
Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. Journal Of The American Academy Of Dermatology 2017, 76: 736-744. PMID: 28139263, PMCID: PMC6035868, DOI: 10.1016/j.jaad.2016.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAlopecia AreataAnti-Inflammatory AgentsAzetidinesClinical Trials as TopicDermatitis, AtopicDermatologic AgentsHumansJanus KinasesMolecular Targeted TherapyNitrilesPiperidinesProtein Kinase InhibitorsPsoriasisPurinesPyrazolesPyrimidinesPyrrolesSignal TransductionSkin DiseasesSulfonamidesVitiligoConceptsJAK inhibitorsSoluble inflammatory mediatorsNew drug classesUseful therapeutic strategyDifferent proinflammatoryAtopic dermatitisInflammatory mediatorsInflammatory dermatosesAlopecia areataDrug classesJanus kinase-signal transducerTherapeutic strategiesJAK inhibitionDermatologic therapyKinase-signal transducerTargeted therapeuticsActivator of transcriptionDermatologyJAK-STATInhibitorsPromising new classEarlier reportsInhibition
2016
Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib
King B, Lee AI, Choi J. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. Journal Of Investigative Dermatology 2016, 137: 951-954. PMID: 27887955, PMCID: PMC5387413, DOI: 10.1016/j.jid.2016.10.044.Peer-Reviewed Original ResearchTopical Ruxolitinib for the Treatment of Alopecia Universalis
Craiglow BG, Tavares D, King BA. Topical Ruxolitinib for the Treatment of Alopecia Universalis. JAMA Dermatology 2016, 152: 490. PMID: 26649829, DOI: 10.1001/jamadermatol.2015.4445.Peer-Reviewed Original Research